Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients

Incidence, kinetics, and risk factors of Epstein–Barr virus viremia in pediatric patients after allogeneic stem cell transplantation

“…The present study demonstrates the frequency of EBV viremia in pediatric allo‐HSCT after in vivo T‐cell depletion. The most important risk factor in this cohort was the use of in vivo T‐cell depletion with ATG or alemtuzumab (15–18). The higher incidence of EBV viremia in MUDs is also related to the standard use of ATG or alemtuzumab for this group.…”

Epstein-Barr Viral Load and Disease Prediction in a Large Cohort of Allogeneic Stem Cell Transplant Recipients

“…The grafts were unmanipulated. The clinical and transplantation data for the patients were described in detail elsewhere by Juvonen et al [21].…”

The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases

“…16,17 As a tool for detecting subclinical EBV 1 disease, one study demonstrated that the majority of deceased allogeneic bone marrow transplant patients with detectable cell-free EBV DNA were found to have PTLD at autopsy, whereas no patient with undetectable cell-free EBV DNA was diagnosed with PTLD post-mortem. 18 As a prognostic marker in EBV 1 hematologic malignancies, cell-free EBV DNA has been shown to be associated with survival outcomes in HL and extranodal natural killer/T-cell lymphoma (ENKTL), as well as complement or correlate with other blood-based prognostic markers, such as serum survivin in ENKTL and soluble CD163 in HL. [19][20][21][22][23] Across a range of lymphomas, there is mounting evidence that the serial assessment of cellfree EBV DNA copy number can inform the dynamics of EBV 1 disease status during and following therapy.…”